The Company is responsible for all costs of the study with Roche supplying their drug atezolizumab representing a cost savings for the

filing / Aug 10, 2026 / receipt

study with Regeneron supplying their drug cemiplimab representing a cost savings for the Company, the first phase of which is expected

filing / Aug 10, 2026 / receipt

The Company is responsible for all costs of the study with Roche supplying their drug atezolizumab representing a cost savings for the

filing / May 11, 2026 / receipt

study with Regeneron supplying their drug cemiplimab representing a cost savings for the Company, the first phase of which is expected

filing / May 11, 2026 / receipt

A Multicenter, Open-label, Dose-Finding Phase 2 Trial Evaluating the Safety and Efficacy of Ateganosine (THIO) Administered in Sequence with Libtayo® (cemiplimab) in NSCLC Patients Who Are Resistant t

ir_statement / Aug 8, 2026 / receipt

Expansion / Registration (NSCLC 3L)

ir_statement / Aug 8, 2026 / receipt

Part C enrollment started in Jul’25

ir_statement / Aug 8, 2026 / receipt

Total of 79 patients enrolled (24 treated in 60mg dose group, 41 in 180mg, and 14 in 360mg)

ir_statement / Aug 8, 2026 / receipt

Up to 148 patients - Part C enrollment started in Jul’25

ir_statement / Aug 8, 2026 / receipt

Trials in solid tumors, such as Breast, Prostate, Gastric, Pancreatic and Ovarian may be pursued via investigator sponsored trials.

ir_statement / Aug 8, 2026 / receipt

Developing agents for the top tumor types markets globally

ir_statement / Aug 8, 2026 / receipt

OS final analysis: potential full commercial approval with very high PTS

ir_statement / Aug 8, 2026 / receipt